References
- Dring LG, Smith RL, Williams RT. The metabolic fate of amphetamine in man and other species. Biochemical Journal 1970; 116: 425–435
- Hollister LE, Prusmack JJ, Paulsen JA, Rosenquist N. Comparison of three psychotropic drugs (psilocybin, JB-329, and IT-290) in volunteer subjects. Journal of Nervous and Mental Disease 1960; 131: 428–434
- Ishida T, Kudo K, Kiyoshima A, Inoue H, Tsuji A, Ikeda N. Sensitive determination of alpha-methyltryptamine (AMT) and 5-methoxy-N,N-diisopropyltryptamine (5MeO-DIPT) in whole blood and urine using gas chromatography-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2005; 823: 47–52
- Murphree HB, Dippy RH, Jenney EH, Pfeiffer CC. Effects in normal man of α-methyltryptamine and α-ethyltryptamine. Clinical Pharmacology and Therapeutics 1961; 2: 722–726
- Poch GK, Klette KL, Hallare DA, Manglicmot MG, Czarny RJ, McWhorter LK, Anderson CJ. Detection of metabolites of lysergic acid diethylamide (LSD) in human urine specimens: 2-oxo-3-hydroxy-LSD, a prevalent metabolite of LSD. Journal of Chromatography B: Biomedical Sciences and Applications 1999; 724: 23–33
- Shulgin A, Shulgin A. #48 α-MT. TiHKAL: A continuation., D Joy. Transform Press, Berkeley, CA 1997; 565–569
- US Drug Enforcement Administration (US DEA), Department of Justice. Schedules of controlled substances: Placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Federal Register 2004; 69: 58050–58053
- Vorce SP, Sklerov JH. A general screening and confirmation approach to the analysis of designer tryptamines and phenethylamines in blood and urine using GC-EI-MS and HPLC-electrospray-MS. Journal of Analytical Toxicology 2004; 28: 407–410